Synthetic Blood International, Inc. Release: Patient Treatment Completed In Synthetic Blood Traumatic Brain Injury Trial; Oxycyte Administration Increases Brain Oxygen Tension In All Trial Patients; Announcement of Preliminary Analysis Of Trial Data Expec

COSTA MESA, Calif.--(BUSINESS WIRE)--Aug. 28, 2006--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced the completion of treatment in the Company’s Phase IIa open-label, proof-of-concept Oxycyte(TM) study in traumatic brain injury. Oxycyte administration increased oxygen tension over baseline in all eight evaluable trial patients. The Company expects to announce results of preliminary data analysis from this trial in the 4th quarter.